Canada: Federal Court Determines Minister’s Decisions Granting NOCs Based On Administrative ANDSs Cross-Referencing Licensed Generics Without Requiring NOAs Are Wrong

Last Updated: January 19 2015
Article by Kelly A. McClellan, PhD. and Jennifer L. Wilkie

Most Read Contributor in Canada, October 2018

On December 19, 2014, the Federal Court set aside a decision of the Minister of Health granting a Notice of Compliance (NOC) to Teva authorizing the sale of its product that referred to Pfizer's Aromasin®. In a separate decision of the same date, the Court declared that the Minister had no entitlement to grant NOCs to Cobalt and Sandoz authorizing sale of products that referred to Actelion's Tracleer®.1

Justice Gleason found the Minister's amendments to its Guidance Document that permitted issuing NOCs to generics submitting an administrative ANDS without having served a Notice of Allegation (NOA) on the holder of the listed patent contravened the Patent Medicines (Notice of Compliance) Regulations, SOR/93-133 (the Regulations).

She also upheld the purpose of Regulations as that of balancing the interests of patentees entitled to protection for legitimately patented innovations while allowing generic companies to early work patented medicines.


Pfizer markets Aromasin, a drug for the treatment of breast cancer and owns Canadian Patent 2,409,059 that is listed on the Patent Register in relation to Aromasin. The Minister issued NOCs to two separate companies seeking to manufacture generic versions that both referenced Pfizer's Aromasin. A first NOC was issued to Generic Medical Partners Inc. (GMP), following Pfizer's decision not to initiate proceedings under the Regulations in response GMP's NOA because GMP does not sell products in Canada. A second NOC issued to Teva. This NOC followed from an administrative ANDS Teva filed based on a licensing agreement it had with GMP and for which Health Canada determined referred to Pfizer's Aromasin product.2

Since Teva had not served Pfizer with an NOA, Pfizer sought judicial review of the Minister's decision to issue an NOC to Teva.

Actelion markets Tracleer, a hypertension drug, and owned Canadian Patent 2,071,193 that was listed on the Patent Register in relation to Tracleer. After settlement of a proceeding with Pharmascience under the Regulations, Pharmascience received a NOC. Shortly thereafter, without having addressed the Regulations, NOCs were issued by the Minister to Cobalt and Sandoz, both of whom had been licensed by Pharmascience.

Since neither Cobalt nor Sandoz had served an NOA, Actelion sought judicial review of the Minister's decision.


In both cases, it was submitted that second persons seeking a NOC with reference to an innovator's product are obliged by subsection 5(1) of the Regulations to serve an NOA in respect of listed patents and that the Minister contravened section 7(1) by issuing NOCs.3

The Minister defended its decisions claiming they were made in accordance with amendments made in 2012 to its Guidance Document, Patented Medicines (Notice of Compliance) Regulations. These amendments allowed the Minister to issue NOCs to generic companies seeking to market drugs referencing patents on the Patent Register without first having served an NOA, so long as the generic company had been licensed to sell the drug by another company that had complied with section 5.4

The Minister claimed these amendments were based on its interpretation of the Regulations, submitting such an interpretation should be afforded deference by the Court for two reasons. First, the interpretation of the Regulations is within the significant expertise of the Minister and officials at the Office of Patent Medicine and Liaison. Second, the change in practice set out in the amendments represented valid policy choices of the Minister.5

Moreover, the Minister also submitted its interpretation of the Regulations in its Guidance Document was correct. It claimed Teva's administrative ANDS did not amount to a "submission for a NOC" within subsection 5(1) because the purpose of the Regulations is limited to preventing infringement by generics who take advantage of the early working exception to develop a generic version of a patented medicine. For example, according to the Minister, GMP and not Teva, took advantage of the early working exception, and GMP had conformed with the Regulations by filing an ANDS for the NOC and serving Pfizer with an NOA.6

In thorough reasons, Justice Gleason set aside the Minister's decisions, disagreeing with the Minister's submissions.

First, Justice Gleason determined the Court did not owe deference to the Minister's decision to issue a NOC because she found no statutory or regulatory support in the Regulations granting the Minister a policy making role to determine when a NOC may be issued. Nor did she consider it within the expertise of the Minister or departmental officials to make such determinations. Rather, she found the mandatory criteria in section 7 prevent the Minister from issuing NOC until those criteria are met and leave the ultimate determinations of whether NOC should be issued to the Court.7

Moreover, disagreeing with the Minister's interpretation of subsection 5(1), she concluded the Minister's amendments to its Guidance Document that permitted it to issue NOCs following administrative ANDS submissions such as Teva's, Cobalt's and Sandoz's contravened the Regulations.8

Instead she found the purpose of the Regulations is to balance the interests of patentees entitled to protection for legitimately patented innovations with allowing generic companies to early work patented medicines. Relying on the Supreme Court decision in Biolyse, and the 2006 regulatory impact analysis statement accompanying the Regulations, she found that generic companies making comparisons to innovator drugs must comply with the obligation in subsection 5(1) to serve an NOA, irrespective of whether the generic had, in fact, early worked the invention.9

Further, Justice Gleason found that the generic manufacturers were required to address the listed patents prior to the Minister's issuance of the NOC. Applying prior interpretations of subsection 5(1) by the Federal Court of Appeal in Nu-Pharm 1 and Nu-Pharm 2, that all generics who obtain rights through a license are required to address innovator's listed patents, she found these submissions for NOCs amounted to one that made a direct or indirect comparison to Aromasin or Tracleer within the meaning of subsection 5(1). As a result, each of Teva, on the one hand, and Cobalt and Sandoz, on the other hand, was obliged to serve an NOA.10

As such, Justice Gleason found the Minister was not entitled to issue the respective NOCs without requiring compliance with subsection 5(1) as this contravened subsection 7(1) of the Regulations.11

The Pfizer case may be found here. The Actelion case may be found here.

Actelion was represented by Gowlings lawyers John Norman and Alex Gloor.


[1] Pfizer Canada Inc. v Canada (Attorney General) and Teva Canada Ltd, 2014 FC 1243 (Pfizer Reasons); Actelion Pharmaceuticals Canada Inc. v Attorney-General of Canada and Pharmascience Inc. et al., 2014 FC 1249 (Actelion Reasons). The Court in the Actelion case granted the declaratory relief sought but indicated that the issue of setting aside the NOCs appeared to be moot as the patent had since expired. The Court also noted that its substantive reasons were set out in the concurrent Pfizer reasons. (See Actelion Reasons at para 9).

[2] Pfizer Reasons at para 36-46

[3] Pfizer Reasons at para 47

[4] Pfizer Reasons at para 33 and 51

[5] Pfizer Reasons at para 51

[6] Pfizer Reasons at para 122-125

[7] Pfizer Reasons at para 113-116

[8] Pfizer Reasons at para 122 and 132; Actelion Reasons at para 9

[9] Bristol Myers Squibb co. v Canada (Attorney General), 2005 SCC 26 (Biolyse); Regulatory Impact Analysis Statement, (2006) C Gaz II, 1510; Pfizer Reasons at Para 133-135

[10] Nu Pharm Inc. v Canada (Attorney General) (1998) 80 CPR (3d) 74 (Nu-Pharm 1); Nu Pharm Inc v Merck & Co (2000), 5 CPR (4th) 138 (Nu-Pharm 2) Pfizer Reasons at Para 141 and 145, Actelion reasons at para 9

[11] Pfizer Reasons at Para 145; Actelion reasons at para 9

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions